Taiwo Adesoye1, Oluwatowo Babayemi2, Lauren M Postlewait3, Sarah M DeSnyder1,4, Susie X Sun1,4, Wendy A Woodward4,5, Naoto T Ueno4,6, Kelly K Hunt1, Anthony Lucci1,4, Mediget Teshome7,8. 1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Health Services Research, Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Division of Surgical Oncology, Department of Surgery, Emory University, Atlanta, GA, USA. 4. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. MTeshome@mdanderson.org. 8. Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. MTeshome@mdanderson.org.
Abstract
BACKGROUND: Inflammatory breast cancer (IBC) is a rare breast malignancy with poor outcomes compared with non-IBC. Age-related differences in tumor biology, treatment, and clinical outcomes have been described in non-IBC. This study evaluated age-related differences in IBC. METHODS: From an institutional prospective database, patients with an IBC diagnosed from 2010 to 2019 were identified. Age was categorized as 40 years or younger, 41 to 64 years, and 65 years or older. Demographics, clinicopathologic features, and treatment received were compared. Recurrence and survival outcomes were analyzed using the log-rank test and the Cox proportional hazards model. RESULTS: Of 523 IBC patients, 113 (21.6%) were age 40 years or younger, and 72 (13.8%) were age 65 years or older. The groups did not differ statistically by race/ethnicity, N stage, clinical stage, or tumor subtype. The younger patients included a higher proportion of Hispanic and Asian patients, triple-negative breast cancer (TNBC), and clinical N2/N3. Trimodality therapy was received by 92% of the stage 3 patients, with no difference in pathologic complete response (pCR) by age (23.3% vs 28.6%; p = 0.46). During a median follow-up period of 40 months, 17% of the patients experienced locoregional recurrence and 42.8% had distant metastasis. No difference in 3-year recurrence-free survival (57.9% vs 42.6% vs 54%; p = 0.42, log rank) or overall survival (OS) (75.6% vs 77.1% vs 64.4%; p = 0.31, log rank) by age was observed, and no difference in OS by age in de novo stage 4 disease was observed. In the multivariate analysis, worse OS was associated with TNBC (hazard ratio [HR], 1.99, 95% confidence interval [CI], 1.31-3.05) and no pCR (HR, 4.45; 95% CI, 2.16-9.18). CONCLUSION: No significant differences were observed in demographics, treatment patterns, or clinical outcomes for IBC patients age 40 years or younger compared with those age 65 years or older treated by a specialized multidisciplinary team. These findings do not support age-related treatment de-escalation in IBC.
BACKGROUND:Inflammatory breast cancer (IBC) is a rare breast malignancy with poor outcomes compared with non-IBC. Age-related differences in tumor biology, treatment, and clinical outcomes have been described in non-IBC. This study evaluated age-related differences in IBC. METHODS: From an institutional prospective database, patients with an IBC diagnosed from 2010 to 2019 were identified. Age was categorized as 40 years or younger, 41 to 64 years, and 65 years or older. Demographics, clinicopathologic features, and treatment received were compared. Recurrence and survival outcomes were analyzed using the log-rank test and the Cox proportional hazards model. RESULTS: Of 523 IBC patients, 113 (21.6%) were age 40 years or younger, and 72 (13.8%) were age 65 years or older. The groups did not differ statistically by race/ethnicity, N stage, clinical stage, or tumor subtype. The younger patients included a higher proportion of Hispanic and Asian patients, triple-negative breast cancer (TNBC), and clinical N2/N3. Trimodality therapy was received by 92% of the stage 3 patients, with no difference in pathologic complete response (pCR) by age (23.3% vs 28.6%; p = 0.46). During a median follow-up period of 40 months, 17% of the patients experienced locoregional recurrence and 42.8% had distant metastasis. No difference in 3-year recurrence-free survival (57.9% vs 42.6% vs 54%; p = 0.42, log rank) or overall survival (OS) (75.6% vs 77.1% vs 64.4%; p = 0.31, log rank) by age was observed, and no difference in OS by age in de novo stage 4 disease was observed. In the multivariate analysis, worse OS was associated with TNBC (hazard ratio [HR], 1.99, 95% confidence interval [CI], 1.31-3.05) and no pCR (HR, 4.45; 95% CI, 2.16-9.18). CONCLUSION: No significant differences were observed in demographics, treatment patterns, or clinical outcomes for IBC patientsage 40 years or younger compared with those age 65 years or older treated by a specialized multidisciplinary team. These findings do not support age-related treatment de-escalation in IBC.
Authors: Tamer M Fouad; Takahiro Kogawa; Diane D Liu; Yu Shen; Hiroko Masuda; Randa El-Zein; Wendy A Woodward; Mariana Chavez-MacGregor; Ricardo H Alvarez; Banu Arun; Anthony Lucci; Savitri Krishnamurthy; Gildy Babiera; Thomas A Buchholz; Vicente Valero; Naoto T Ueno Journal: Breast Cancer Res Treat Date: 2015-07 Impact factor: 4.872
Authors: Tamer M Fouad; Angelica M Gutierrez Barrera; James M Reuben; Anthony Lucci; Wendy A Woodward; Michael C Stauder; Bora Lim; Sarah M DeSnyder; Banu Arun; Babiera Gildy; Vicente Valero; Gabriel N Hortobagyi; Naoto T Ueno Journal: Lancet Oncol Date: 2017-04 Impact factor: 41.316
Authors: D J P van Uden; H W M van Laarhoven; A H Westenberg; J H W de Wilt; C F J M Blanken-Peeters Journal: Crit Rev Oncol Hematol Date: 2014-10-16 Impact factor: 6.312
Authors: Georgiana K Ellis; William E Barlow; Julie R Gralow; Gabriel N Hortobagyi; Christy A Russell; Melanie E Royce; Edith A Perez; Danika Lew; Robert B Livingston Journal: J Clin Oncol Date: 2011-01-10 Impact factor: 44.544
Authors: Shaheenah Dawood; Naoto T Ueno; Vicente Valero; Wendy A Woodward; Thomas A Buchholz; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo; Massimo Cristofanilli Journal: Cancer Date: 2010-11-29 Impact factor: 6.860
Authors: Massimo Cristofanilli; Vicente Valero; Aman U Buzdar; Shu-Wan Kau; Kristine R Broglio; Ana Maria Gonzalez-Angulo; Nour Sneige; Rabiul Islam; Naoto T Ueno; Thomas A Buchholz; Sonja E Singletary; Gabriel N Hortobagyi Journal: Cancer Date: 2007-10-01 Impact factor: 6.860
Authors: Ewan K A Millar; Peter H Graham; Sandra A O'Toole; Catriona M McNeil; Lois Browne; Adrienne L Morey; Sarah Eggleton; Julia Beretov; Constantine Theocharous; Anne Capp; Elias Nasser; John H Kearsley; Geoff Delaney; George Papadatos; Christopher Fox; Robert L Sutherland Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Wendy A Woodward; Massimo Cristofanilli; Sofia D Merajver; Steven Van Laere; Lajos Pusztai; Francois Bertucci; Fedor Berditchevski; Kornelia Polyak; Beth Overmoyer; Gayathri R Devi; Esta Sterneck; Robert Schneider; Bisrat G Debeb; Xiaoping Wang; Kenneth L van Golen; Randa El-Zein; Omar M Rahal; Angela Alexander; James M Reuben; Savitri Krishnamurthy; Anthony Lucci; Naoto T Ueno Journal: J Cancer Date: 2017-10-09 Impact factor: 4.207
Authors: Dominique J P van Uden; Marissa C van Maaren; Peter Bult; Luc J A Strobbe; J J M van der Hoeven; Charlotte F J M Blanken-Peeters; Sabine Siesling; Johannes H W de Wilt Journal: Breast Cancer Res Treat Date: 2019-04-10 Impact factor: 4.872
Authors: Lauren M Drapalik; Jonathan J Hue; Ashley Simpson; Mary Freyvogel; Lisa Rock; Robert R Shenk; Amanda L Amin; Megan E Miller Journal: Ann Surg Oncol Date: 2022-08-08 Impact factor: 4.339